Arrow, K. J. 1950. A difficulty in the concept of social welfare. Journal of Political Economy 58(4):328–346.
Arrow, K. J. 1963. Social choice and individual values. 2nd ed. New York: John Wiley & Sons.
Bagnoli, F., B. Baudner, R. P. Mishra, E. Bartolini, L. Fiaschi, P. Mariotti, V. Nardi-Dei, P. Boucher, and R. Rappuoli. 2011. Designing the next generation of vaccines for global public health. OMICS: A Journal of Integrative Biology 15(9):545–566.
Barron, F. H., and B. Barrett. 1996. The efficacy of SMARTER—Simple multi-attribute rating technique extended to ranking. Acta Psychologica 93(1):23–36.
Batson, A. 2005. The problems and promise of vaccine markets in developing countries. Health Affairs 24(3):690–693.
Bishai, D. M., C. Champion, M. E. Steele, and L. Thompson. 2011. Product development partnerships hit their stride: Lessons from developing a meningitis vaccine for Africa. Health Affairs 30(6):1058–1064.
Bloom, D. E., D. Canning, and M. Weston. 2005. The value of vaccination. World Economics 6(3):15–40.
Brilliant, L., and W. Foege. 2013. Lessons from smallpox guide polio endgame. Scientific American, April 22. http://blogs.scientificamerican.com/guest-blog/2013/04/22/lessons-from-smallpox-guide-polio-endgame (accessed May 31, 2013).
Drummond, M., C. Chevat, and M. Lothgren. 2007. Do we fully understand the economic value of vaccines? Vaccine 25(32):5945–5957.
Edwards, W., and F. H. Barron. 1994. SMARTS and SMARTER: Improved simple methods for multiattribute utility measurement. Organizational Behavior and Human Decision Processes 60(3):306–325.
HHS (U.S. Department of Health and Human Services). 2010. The 2010 National Vaccine Plan, protecting the nation’s health through immunization. http://www.hhs.gov/nvpo/vacc_plan/2010%20Plan/nationalvaccineplan.pdf (accessed May 31, 2013).
IOM (Institute of Medicine). 1985. New vaccine development: Establishing priorities. Volume I, diseases of importance in the United States. Washington, DC: National Academy Press.
IOM. 1986. New vaccine development: Establishing priorities. Volume II, Diseases of importance in developing countries. Washington, DC: National Academy Press.
IOM. 2000. Vaccines for the 21st century: A tool for decisionmaking. Washington, DC: National Academy Press.
IOM. 2012. Ranking Vaccines: A prioritization framework: Phase I: Demonstration of concept and a software blueprint. Washington, DC: The National Academies Press.
Keeney, R., and H. Raiffa. 1976. Decisions with multiple objectives: Preferences and value tradeoffs. New York: John Wiley & Sons.
Milstien, J., and B. Candries. 2002. Economics of vaccine development and implementation: Changes over the past 20 years. Bethesda, MD: U.S. Department of Health and Human Services, National Institute of Health, National Institute of Allergy and Infectious Diseases.
Rappuoli, R., and A. Alderem. 2011. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473(7348):463–469.
Rappuoli, R., S. Black, and P. H. Lambert. 2011. Vaccine discovery and translation of new vaccine technology. Lancet 378(9788):360–368.
Tomori, O. 2011. From smallpox eradication to the future of global health: Innovations, application and lessons for future eradication and control initiatives. Vaccine 29(Suppl. 4):D145–D148.
